Effects of psychotropic switches on weight change: a prospective cohort study
| Autor: | M. Piras, S. Ranjbar, C. Dubath, N. Laaboub, C. Grosu, F. Gamma, K. Von Plessen, A. Von Gunten, P. Conus, C. Eap |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | European Psychiatry, Vol 65, Pp S731-S731 (2022) |
| Druh dokumentu: | article |
| ISSN: | 0924-9338 1778-3585 |
| DOI: | 10.1192/j.eurpsy.2022.1887 |
| Popis: | Introduction Many psychotropic drugs can induce weight gain with differences in their metabolic risk profiles (i.e. high, medium or low-risk). Objectives To compare the weight evolution of patients switching versus patients keeping their psychotropic drugs with different risk-profiles. Methods Data for patients switching or keeping the same drug were obtained from the Psyclin (from 2007 to 2015) and Psymetab (2007- 2019) cohort studies, conducted at the Lausanne University Hospital, Switzerland. Patients either switched from a high to a low-risk, a high to a medium-risk, a medium to a low-risk drug, or for a drug with the same risk category. Patients not switching either kept a high, medium or low-risk drug. The evolution of weight is currently being analyzed using a linear mixed-effect model. Results Preliminary results showed that switching from a high to low-risk molecule had the strongest impact on weight changes. The analysis being ongoing, the quantitative results will be presented at the congress. Conclusions Switching from a high-risk to a low-risk molecule is likely to have the strongest impact on weight changes. Disclosure No significant relationships. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|